MBMariya Vladimirovna Berkut

Mariya Vladimirovna Berkut

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariya Vladimirovna Berkut has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incidence and one-year mortality of penile cancer in the Russian Federation. Part 1

    by V. M. Merabishvili, Мерабишвили В. М., Mariya V. Berkut, Беркут Мария Владимировна, P. M. Gorlin, Горлин П. М., A. K. Nosov, Носов А. К.

    Background. Penile cancer is a rare malignant tumor: its prevalence ranges from 0.1 to 5.9 cases per 100,000 men. This type of cancer is very often left out due to the rarely correctly diagnosed disease and the lack of awareness among the male population about the need to regularly prevent checkups with an urologist. The rates depend significantly on the region, but in less populated regions, morbidity and mortality are significantly lower than in large cities due to the lack of diagnostic measures and the low frequency of treatment in case of clinical symptoms. Aim. To perform the population-level analysis of temporal trends in the incidence and mortality of penile cancer in the Russian Federation, as well as to evaluate the completeness and quality of case registration for this malignancy. Additionally, patterns of one-year incidence and mortality were examined using data from the population-based cancer registry of the Northwestern Federal District. Materials and methods. Data were obtained from the International Agency for Research on Cancer, the population-based cancer registry of the Northwestern Federal District of the Russian Federation, and the N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation (Saint Petersburg). For detailed assessment of epidemiological characteristics, including one-year incidence and mortality among patients with penile cancer, the database of the Northwestern Federal District population-based cancer registry was analyzed. The overall study cohort comprised 2,728 registered cases of penile cancer. Results and conclusion. From 2000 to 2023, both the absolute number of cases and the age-standardized incidence rate of penile cancer in the Russian Federation demonstrated an increasing trend, with the age-standardized incidence rate rising from 0.54 to 0.98 per 100,000 population. However, since 2019, a declining trend in the age-standardized incidence rate has been observed.

  • Open Access

    Daroluamid in combination with androgen-deprivation therapy as a new method of treatment of mHSPCa

    by Maria V. Berkut, Oleg V. Zaozersky, Petr M. Gorlin, Anastasia G. Kondratyeva, Alexander K. Nosov, М. В. Беркут, О. В. Заозерский, П. М. Горлин, А. Г. Кондратьева, А. К. Носов

    This clinical case report presents the management of a patient with high-volume hormone-sensitive metastatic prostate cancer treated with a combination of darolutamide and androgen deprivation therapy. The treatment choice was driven by significant comorbidities and a high risk of drug–drug interactions, supporting the rationale for selecting a therapy with a favorable safety and interaction profile. The patient achieved a marked clinical benefit, including an undetectable PSA level and partial regression of metastatic lesions. Special attention is given to the clinical relevance of drug–drug interactions and the role of darolutamide in managing elderly patients with polypharmacy.

  • Open Access

    The state of cancer care in Russia: prostate cancer (С61). Observed and relative survival of patients with prostate cancer. Modern treatment options. Part 2. (clinical-population study)

    by Vakhtang M. Merabishvili, Dmitri I. Krivonosov, Maria V. Berkut, Vladimir Y. Startsev, Yulia P. Yurkova, Alexander K. Nosov, Sergey N. Efimov, Юркова Юлия Петровна

    This study is dedicated to analyzing the survival dynamics of patients with prostate cancer (PCa) in the Northwestern Federal District of the Russian Federation over a 25-year period (2000–2024). The relevance of the work is driven by the high growth rate of PCa incidence and the need for an objective assessment of the effectiveness of oncological care at the population level. The aim of the research was to calculate the observed and relative survival rates of patients, as well as to evaluate modern anti-tumor therapy options. The study was based on data from the Population Cancer Registry (PCR) of the Northwestern Federal District of the RF. From a total dataset of 1.6 million observations, a verified sample of 76,206 PCa cases was formed. Calculations were performed in accordance with international standards of the Eurocare program, with authors’ modifications. The analysis demonstrated significant progress in the treatment of PCa patients. Over the studied period, the average one-year observed survival rate increased by 20.2%, reaching 89.4% (relative – 93.5%). The five-year observed survival rate grew from 42.4% (period 2000–2004) to 57.6% (2010–2014), representing a 35.8% increase; the five-year relative survival rate reached 75.3%. One-year mortality decreased by more than half, from 25.6% to 10.6%. Regarding age-related aspects, it was found that the relative one-year survival rates remained consistently high both in the group under 60 years (94.2%) and among older individuals (93.4%), confirming the effectiveness of modern treatment protocols across all age categories.

  • Open Access

    The state of cancer care in Russia: prostate cancer (С61). Morbidity, mortality, quality of accounting, 1-year lethality. Part 1. (clinical-population study)

    by Vakhtang M. Merabishvili, Dmitri I. Krivonosov, Maria V. Berkut, Vladimir Y. Startsev, Yulia P. Yurkova, Alexander K. Nosov, Vladimir V. Perelygin, Юркова Юлия Петровна

    The study is devoted to a comprehensive analysis of the epidemiological situation related to prostate cancer (PCa) in the Russian Federation and the Northwestern Federal District (NWFD). Today, PCa is the leading cause of oncological morbidity among the male population, ranking first (19.1%) in the structure of malignant neoplasms in Russia as of 2023. In the NWFD and Saint Petersburg, these figures reach 19.74% and 21.49%, respectively. The relevance of the work is driven by a steady increase in incidence rates, including among the working-age population, against the backdrop of global trends. The aim of the study is to examine the patterns in the dynamics of incidence and mortality rates, evaluate the quality of reporting for newly registered PCa cases, calculate one-year lethality using the Population-based Cancer Registry (PCR) database of the NWFD, and explore modern diagnostic capabilities. The study established that despite the rising incidence in the NWFD, there is a observed decline in mortality and one-year lethality. A key indicator of improved reporting quality was the decrease in the Data Reliability Index (DRI) to 0.22–0.23 by 2023. Significant progress in early diagnosis was identified: while Stage IV was predominant (33.7%) among men under 60 in the year 2000, by 2023, the diagnosis was verified at Stage II in 43.1% of patients. Similar positive dynamics were observed in the patient group aged 60 and older. The findings indicate an improvement in the screening system and the increased effectiveness of oncological care in the region, which facilitates timely disease detection and improves patient prognosis. The global context of the study confirms a twofold increase in the absolute number of cases in the Russian Federation over the last decades, necessitating further development of preventive and diagnostic measures.

  • Open Access

    The state of cancer care in Russia: malignant neoplasms of the bladder (C67). One- and five-year by age, sex, and clinical characteristics. Contemporary treatment strategies (clinical and population study). Part III

    by V. M. Merabishvili, Mariya V. Berkut, A. K. Nosov, S. S. Bagnenko

    Background. Survival rate calculation remains the key metric in evaluating the performance of cancer care systems. In Russia, only a limited number of administrative regions possess the infrastructure to reliably perform such assessments. The first population-based cancer registry in Russia, established by our team in 1993 and operating in accordance with international standards, significantly expanded these capabilities to the level of a federal district. Utilizing data from the population-based cancer registry of the Northwestern Federal District (NWFD), we currently conduct research reflecting the real state of cancer care delivery in the country. Aim. To analyze survival trends in patients with bladder cancer (BC) in the NWFD of Russia and to assess current therapeutic approaches. Materials and methods. The study was based on a population-based cancer registry dataset comprising over 1.6 million cases, including 31,126 patients diagnosed with BC. Data were processed using standard methods in line with the Eurocare protocols. Results. A marked increase in one-year observed survival was found: from 68.7 % to 75.5 %; as well as in five-year survival: from 42.8 % to 48.4 %. Overall mortality during the observation period declined from 31.3 % to 24.5 %. Among patients under 40 years of age, one-year survival exceeded 90 %, while in the elderly and long-lived cohorts it remained below 50 %. The proportion of patients diagnosed with localized BC increased from 46.9 % to 70.4 %, whereas the rate for advanced disease reached 39.0 %. Patients with stage IV urothelial carcinoma demonstrate the poorest survival outcomes, which is consistent with international epidemiological data. The advent of immunotherapy and targeted agents has marked a new era in the management of the disease, showing improvement in long-term outcomes in selected patient subgroups. Conclusion. The data demonstrate a positive trend in one-year survival among BC patients in the NWFD of Russia, particularly in those diagnosed with localized disease. The improvement in stage distribution and a reduction in unspecified tumor localizations indicate enhanced diagnostic accuracy and higher quality of oncological care.

  • Open Access

    Comparative Analysis of Standard and Split-Dose Cisplatin in Neoadjuvant Chemotherapy for Bladder Cancer

    by Мария Владимировна Беркут, Анна Игоревна Семенова, Алексей Викторович Новик, Дилором Хамидовна Латипова, Гульфия Мидхатовна Телетаева, Екатерина Александровна Шишаева, Александр Константинович Носов

    Введение. Цисплатин-содержащая неоадъювантная химиотерапия (НТ) перед радикальной цистэктомией (РЦЭ) снижает риск смерти от прогрессирования опухоли на 33 % и способствует развитию полного патоморфологического ответа (ППО) у трети пациентов. Однако сравнительная эффективность различных режимов дозирования цисплатина остается недостаточно изученной. Цель. Оценка частоты ППО после НТ у пациентов с мышечно-инвазивным раком мочевого пузыря (МИРМП) в зависимости от режима дозирования цисплатина (40 и 70 мг/м²). Материалы и методы. За период с января 2015 по сентябрь 2024 г. идентифицировано 60 случаев проведения НТ перед РЦЭ на базе отделения онкоурологии ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России. Все исследуемые случаи были разделены на две группы: расщепленное введение цисплатина 40 мг/м2 в два дня (группа А, n = 39 пациентов) и группа стандартного введения цисплатина 70 мг/м2 в один день (n = 21). Всем пациентам по завершению НТ планировалось выполнение РЦЭ. В работу было включено 22 случая (36,7 %) со II стадией заболевания, 28 случаев (46,7 %) IIIA стадии, шесть случаев (10,0 %) при местнораспространенном процессе IIIB и четыре случая (6,7 %) стадии IVB (на фоне проведения НТ были выявлены костные поражения M1b, и лекарственная терапия была этапом многокомпонентного лечения). Анализ проводился в популяции по намерению лечить (intent-to-treat). Результаты. Группы сопоставлялись по базовым характеристикам. Средняя продолжительность лечения в обеих группах составила 10,76 ± 4,38 нед. (95 % ДИ: 9,63–11,89; p = 0,085). Медиана числа проведенных циклов лечения составила 3 (от 1 до 6), при этом в группе В медиана числа циклов была продолжительнее — 4 (p = 0,032). Плотность дозы цисплатина в группе А составила 42 мг/нед. (95 % ДИ: 35–51), а в группе В — 35 мг/нед. (95 % ДИ: 33–43), группы были сопоставимы (р = 0,061). РЦЭ выполнена 40 пациентам, по результатам гистологического исследования выявлено всего шесть случаев (10,0 %) ППО и 15 случаев (25,0 %) снижения стадии заболевания < ypT2N0. При сопоставлении стадий РМП (pTNM) отличий между группами не найдено. Выводы. Частота достижения ППО была сопоставима между разными режимами дозирования цисплатина (40 или 70 мг/м2), однако ни в одном случае не превысила показатель более 10,0 %.

  • Open Access

    The state of cancer care in Russia: malignant neoplasms of the bladder (C67). One-year mortality, details of location and histological structure, modern diagnostics (clinical and population study). Part II

    by V. M. Merabishvili, M. V. Berkut, A. K. Nosov, A. S. Artemyeva, A. S. Mamontova, S. S. Bagnenko

    Background. Assessment of oncological care in the Russian Federation requires reliable and accurate data. A significant step in this direction was taken in 1996 with the issuance of Order No. 420 of the Ministry of Health of the Russian Federation dated December 23, 1996, “On the Creation of the State Cancer Registry”. However, despite this, information databases (DBs) are still underutilized in analytical calculations of most indicators (except for incidence rates). The only exception is the data obtained from the first Population-Based Cancer Registry (PBCR) in Russia established in Saint Petersburg in 1993 which now covers the entire Northwestern Federal District (NWFD) of the Russian Federation. Aim. Based on the extensive database of the PBCR NWFD of the Russian Federation, this study aims to conduct a comparative analysis of cancer registry data and official state reports on one-year mortality rates in patients with bladder cancer (BC). Additionally, it seeks to present detailed description of BC location and histological structure in this patient group and analyze modern diagnostic capabilities for malignant neoplasms of the bladder. Materials and methods. The study is based on a verified database of the PBCR NWFD of the Russian Federation, containing data on more than 31,000 BC patients. Standard oncological statistical methods were applied in the analysis. Results. A decline in the one-year mortality rate among BC patients in the NWFD of the Russian Federation was observed, decreasing from 31.3 % in 2000–2004 to 24.5 % in 2020–2022. Significant changes in tumor locations were noted: the proportion of BC cases (C67.0) in the bladder trigone decreased from 14 to 7.7 %, while the proportion of tumors in the lateral wall (C67.2) increased from 4.1 to 22.1 %. Additionally, there was a rise in cases of unspecified location (C67.9). However, histological structure of BC, classified according to the WHO codes, remained practically unchanged. Conclusion. A positive trend in the reduction of one-year mortality rates among BC patients has been identified. Modern diagnostic methods for BC have been presented highlighting the need for further development of cancer registries to enhance monitoring and assessment of the quality of oncological care in the Russian Federation.

  • Open Access

    Surgical risks in radical cystectomy: experience of a specialized center

    by M. V. Berkut, N. F. Krotov, A. K. Nosov

    Background. Radical cystectomy is the standard treatment for muscle invasive bladder cancer. However, it is associated with a high risk of complications and mortality. Key strategies to reduce these risks include implementation of minimally invasive treatment methods and the Enhanced Recovery After Surgery (ERAS) protocol, as well as identification of factors associated with development of complications.Aim. To analyze 30-day postoperative complications and mortality rates following radical cystectomy taking into account the effect of the ERAS protocol on treatment outcomes.Materials and methods. This retrospective single-center cohort study included surgical treatment outcomes of 455 patients with a confirmed diagnosis of bladder cancer (cTis–4N0–3) who underwent radical cystectomy via either open or laparoscopic approaches. Of these, 344 patients (75.6 %) underwent perioperative rehabilitation following the ERAS principles. The severity of complications was assessed using the Clavien classification as modified by the European Association of Urology. The study protocol was approved by the Biomedical Ethics Committee (No. 32/355 from 23.12.2020).Results. Surgeries in the ERAS group were more frequently performed using minimally invasive techniques (98.5 % vs. 62.2 %; p 0.001), with reduced blood loss and shorter operative times, and were more often accompanied by standard and extended lymphadenectomy (p 0.001). In the ERAS group, ileocecal angle mobilization was performed in 49.4 % of cases, significantly reducing the risk of mechanical and dynamic bowel obstruction by factor of 2.68 (p = 0.006). Median in-hospital time was 9 days shorter in the ERAS group (p 0.001), and overall complication rate was 40.7 % compared to 56.8 % in the standard care group (p = 0.003). Mortality rates did not differ between the groups (1.8 % vs. 2.3 %; p = 1.0).Conclusion. The implementation of the ERAS protocol and minimally invasive techniques in radical cystectomy significantly reduces postoperative complication rates, including the risk of bowel obstruction, shortens hospital stays, and improves overall treatment outcomes.

  • Open Access

    State of oncological care in Russia: bladder cancer (С67). Incidence, quality of patient followup, annual mortality. Part I

    by V. M. Merabishvili, M. V. Berkut, A. K. Nosov, S. S. Bagnenko

    Background. Bladder cancer (С67) remains a serious problem of modern medicine without an established system of active detection. Among male population, bladder cancer is close to such malignant neoplasms as kidney cancer and systemic neoplasms of the lymphatic and hematopoietic tissues, while among female population to oral and brain neoplasms. In terms of 5-year cumulative, observed and relative survival bladder cancer is similar to malignant tumors of the parotid gland (С07) and leukemias (С91–96). Bladder cancer has a higher tendency to recurrence and progression.Aim. To study for the first time on population level current dynamics of morbidity, mortality, accuracy of registering of patients with bladder cancer in Russia and to evaluate specifics of annual mortality of the patients based on the Population Cancer Registry (PCR) database of the Northwestern Federal District of the Russian Federation (NWFD RF).Materials and methods. Materials of the International Agency for the Research on Cancer, P.A. Herzen Moscow Oncology Research Institute and N.N. Petrov National Medical Research Center of Oncology reference books were used. Detailed characteristics of the analytical values were established based on the NWFD RF PCR database. For calculation of annual bladder cancer mortality, 27,431 observations were selected from the PCR database.Results and conclusion. The study allowed to determine the specifics of bladder cancer morbidity in the world, Russia, and NWFD RF, establish age characteristics of the registered bladder cancer cases. Dynamics of bladder cancer morbidity and mortality in Russia and NWFD RF were demonstrated. The negative effect of COVID-19 pandemic was observed. Positive dynamics in mortality and quality of follow-up for patients with bladder cancer were shown. Based in the PCR NWFD RF database, specifics of annual mortality of patients with bladder cancer were determined.

  • Open Access

    Trends and outcomes of bladder cancer treatment over the past decade

    by M. V. Berkut, A. M. Belyaev, A. K. Nosov

    Background: Radical cystectomy (RC) is effectively used for urothelial bladder cancer, however, the risk of recurrence remains high necessitating the search for the new treatment approaches. The aim of this study is to analyze the impact of pre- and postoperative treatments on 10-year overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) in patients diagnosed with bladder cancer (BC).Materials and methods: This retrospective single-center cohort study included the surgical treatment outcomes of 484 patients with confirmed BC diagnosis (cTis-4N0–3) who underwent cystectomy between 2012 and 2021. The final analysis included 455 cases, with a median age of 65 years, and the majority being male (82.6 %). Prior radiation therapy (RT) was administered to 6.4 % of patients, BCG therapy to 5.9 %, and neoadjuvant therapy (NT) to 23.5 %. Among postoperative treatments, only adjuvant systemic therapy (AT) in 49 patients (10.8 %) was considered. The study protocol was approved by the Biomedical Ethics Committee (No. 32 / 355, dated December 23, 2020).Results: Three key trends were identified over the past 10 years. First, the number of NT prescriptions increased by more than 50 %, mainly due to platinum-based regimens and immuno-oncological agents; however, such regimens were rarely used in patients over 75 years old. Second, prior definitive RT was found to be a significant risk factor for recurrence (OR 2.84, p < 0.001), while NT and AT did not impact survival due to the limited number of cases. Third, surgical treatment after RT was not limited to laparoscopic access and did not lead to an increase in positive surgical margins (detected in only one case, 3.4 %).Conclusions: Our study revealed that definitive radiation therapy negatively affects oncological outcomes and increases the risk of recurrence after radical cystectomy, emphasizing the need for a cautious approach when selecting treatment for such patients.